

Wilate (von Willebrand factor/coagulation factor VII complex [human])
Effective 01/01/2024

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
Exceptions	N/A		

Overview
FDA-Approved Indication

1. Wilate is indicated in children and adults with von Willebrand Disease (VWD) for:
 - a. On-demand treatment and control of bleeding episodes
 - b. Perioperative management of bleeding
2. Wilate is indicated in adolescents and adults with hemophilia A for:
 - a. Routine prophylaxis to reduce the frequency of bleeding episodes
 - b. On-demand treatment and control of bleeding episodes

Compendial Use

Acquired von Willebrand Syndrome

All other indications are considered experimental/investigational and not medically necessary.

Coverage Guidelines

Authorization may be granted for members new to the plan who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorizations may be granted for members who meet all diagnosis-specific criteria and documentation has been provided.

1. Must be prescribed by or in consultation with a hematologist.
 - A. Von Willebrand Disease**
 1. Member has type 1, 2A, 2M, or 2N VWD and has had an insufficient response to desmopressin or a documented clinical reason for not using desmopressin (see Appendix B) OR
 2. Member has type 2B or type 3 VWD.
 - B. Acquired von Willebrand Syndrome**

Authorization may be granted for treatment of acquired von Willebrand syndrome.

C. Hemophilia A

1. Member has mild disease (see Appendix A) and has had an insufficient response to desmopressin or a documented clinical reason for not using desmopressin (see Appendix B) OR
2. Member has moderate or severe disease (see Appendix A).

Continuation of Therapy

Authorization may be granted for continued treatment in members requesting reauthorization for an indication listed above when the member is experiencing benefit from therapy (e.g., reduced frequency or severity of bleeds).

Limitations

Approvals will be granted for 12 months.

Appendix

Appendix A: Classification of Hemophilia by Clotting Factor Level (% Activity) and Bleeding Episodes

Severity	Clotting Factor Level % activity*	Bleeding Episodes
Severe	<1%	Spontaneous bleeding episodes, predominantly into joints and muscles Severe bleeding with trauma, injury or surgery
Moderate	1% to 5%	Occasional spontaneous bleeding episodes Severe bleeding with trauma, injury or surgery
Mild	6% to 40%	Severe bleeding with serious injury, trauma or surgery

*Factor assay levels are required to determine the diagnosis and are of value in monitoring treatment response.

Appendix B: Clinical Reasons For Not Utilizing Desmopressin in Patients with Hemophilia A and Type 1, 2A, 2M and 2N VWD

- A. Age < 2 years
- B. Pregnancy
- C. Fluid/electrolyte imbalance
- D. High risk for cardiovascular or cerebrovascular disease (especially the elderly)
- E. Predisposition to thrombus formation
- F. Trauma requiring surgery
- G. Life-threatening bleed
- H. Contraindication or intolerance to desmopressin
- I. Severe type 1 von Willebrand disease
- J. Stimate Nasal Spray is unavailable due to backorder/shortage issues (where applicable)

References



1. Wilate [package insert]. Hoboken, NJ: Octapharma USA Inc.; November 2019.
2. National Institutes of Health. The diagnosis, evaluation, and management of von Willebrand disease. Bethesda, MD: US Dept of Health and Human Services, National Institutes of Health; 2007. NIH publication No. 08-5832.
3. Tiede A, Rand J, Budde U, et al. How I treat the acquired von Willebrand syndrome. *Blood*. 2011;117(25):6777-85.
4. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. *Haemophilia*. 2020 Aug;26 Suppl 6:1-158.
5. Federici A, Budde U, Castaman G, Rand J, Tiede A. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. *Semin Thromb Hemost*. 2013;39(2):191-201.
6. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. Revised March 2022. MASAC Document #272. https://www.hemophilia.org/sites/default/files/document/files/272_Treatment.pdf. Accessed October 3, 2022.
7. National Hemophilia Foundation. MASAC recommendations regarding the treatment of von Willebrand disease. Revised February 2021. MASAC Document #266. <https://www.hemophilia.org/sites/default/files/document/files/266.pdf> . Accessed October 3, 2022.
8. Stimate [package insert]. King of Prussia, PA: CSL Behring LLC; June 2021.
9. Leissinger C, Carcao M, Gill JC, et al. Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders. *Haemophilia*. 2014;20:158-167.

Review History

12/13/2023: Reviewed at Dec P&T, switched from SGM to Custom. Effective 1/1/2024

